COVID-19 more commonly known as the Coronavirus has disrupted life across all sectors, and the pharmaceutical industry has taken the biggest brunt exposing international drug shortage, insufficient global supply chain and inefficient cross-communication between pharmaceutical giants worldwide. These shortcomings are being termed as the key players in the delay of announcing a coherent treatment and/or preventive measure against Coronavirus.